Literature DB >> 22222922

Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy.

Sergio Copete1, Jose M Ruiz-Moreno, Carlos Cava, Javier A Montero.   

Abstract

OBJECTIVE: To evaluate changes in neural retina (NR) thickness and best-corrected visual acuity (BCVA) induced by treatment of chronic central serous chorioretinopathy (CSC) by photodynamic therapy (PDT). PATIENTS AND METHODS: Retrospective study of 25 eyes of 25 patients with chronic CSC treated by "full-fluence" PDT. LogMAR BCVA and Stratus optical coherence tomography (OCT) were evaluated before treatment and 1 year after PDT. Twenty-four eyes from 24 patients with non-chronic, non-PDT-treated forms of CSC were evaluated as a control group.
RESULTS: NR foveal thickness before PDT was 182 ± 43.4 μm (range, 92-246) vs 148.1 ± 30.9 μm (range, 101-220) 1 year after treatment (p = 0.004; Student's t-test paired data). NR foveal thickness in the untreated eyes was 204.6 ± 30.7 μ (range, 132-249) vs 192.5 ± 26.4 μ (range, 123-235) after self-resolution (p = 0.03; Student's t-test paired data). Basal NR thickness was statistically significant different between both groups (p = 0.04; Student's t-test); this difference continued to be significant at the end of the follow-up (p < 0.01; Student's t-test). All the patients with chronic CSC treated by PDT showed anatomic resolution, and BCVA improved from 0.38 ± 0.35 to 0.23 ± 0.29 (p = 0.007; Student's t-test paired data). Final BCVA and basal and final NR thickness showed poor correlation (Pearson = 0.2 and 0.1 respectively).
CONCLUSIONS: The use of PDT in chronic CSC induces NR thickness thinning. This change is not correlated with a decrease in BCVA. Spontaneous resolution of classic CCS also showed significant NR thinning.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222922     DOI: 10.1007/s00417-011-1900-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  35 in total

1.  Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.

Authors:  Arif Koytak; Kazim Erol; Erol Coskun; Nihal Asik; Hakan Öztürk; Yusuf Özertürk
Journal:  Retina       Date:  2010 Nov-Dec       Impact factor: 4.256

2.  Retinal atrophy in idiopathic central serous chorioretinopathy.

Authors:  Maria S M Wang; Birgit Sander; Michael Larsen
Journal:  Am J Ophthalmol       Date:  2002-06       Impact factor: 5.258

3.  Photodynamic effects on choroidal neovascularization and physiological choroid.

Authors:  Ursula Schmidt-Erfurth; Stephan Michels; Irene Barbazetto; Horst Laqua
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

4.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

5.  Photodynamic therapy in the treatment of chronic central serous chorioretinopathy.

Authors:  C Valmaggia; H Niederberger
Journal:  Klin Monbl Augenheilkd       Date:  2006-05       Impact factor: 0.700

6.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

7.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

8.  Long-term follow-up of central serous chorioretinopathy.

Authors:  C M Gilbert; S L Owens; P D Smith; S L Fine
Journal:  Br J Ophthalmol       Date:  1984-11       Impact factor: 4.638

9.  Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Authors:  Ursula Schlötzer-Schrehardt; Arne Viestenz; Gottfried O H Naumann; Horst Laqua; S Michels; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-27       Impact factor: 3.117

10.  Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; Emily W H Tang; David T L Liu; Dennis S C Lam
Journal:  Retina       Date:  2008-01       Impact factor: 4.256

View more
  5 in total

1.  Retinal sensitivity assessed by microperimetry and corresponding retinal structure and thickness in resolved central serous chorioretinopathy.

Authors:  H W Chung; C M Yun; J T Kim; S-W Kim; J Oh; K Huh
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

2.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

3.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

4.  A two-year study of diffused retinal pigment epitheliopathy treated with half-dose photodynamic therapy guided by simultaneous angiography and optical coherence tomography.

Authors:  Yang Liu; Lei Li; Elena Yingqiu Zhu; Yuanzhi Yuan; Wenji Wang; Gezhi Xu
Journal:  Eye (Lond)       Date:  2018-12-07       Impact factor: 3.775

Review 5.  Advances in the treatment of central serous chorioretinopathy.

Authors:  Marwan A Abouammoh
Journal:  Saudi J Ophthalmol       Date:  2015-01-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.